Eli Lilly & Co. (LLY)

82.66
0.44 0.54
NYSE : Health Technology
Prev Close 82.22
Open 81.71
Day Low/High 81.61 / 82.92
52 Wk Low/High 73.69 / 89.09
Volume 2.42M
Avg Volume 4.15M
Exchange NYSE
Shares Outstanding 1.09B
Market Cap 88.82B
EPS -0.20
P/E Ratio N/A
Div & Yield 2.25 (2.59%)

Latest News

Elanco, Heifer International 10-Year Effort Breaks The Cycle Of Hunger For 160,000 Families

Research finds gifting livestock improves diets, incomes, lessens poverty

Jim's Daily Rundown

Jim discusses his thoughts on Kohl's quarter, a Raytheon downgrade, 3M, and answers a club member's question.

Possible Shift in Medicare Drug Organization May Give Pharma Heartburn

Possible Shift in Medicare Drug Organization May Give Pharma Heartburn

President Trump has been all bluster and tweets when it comes to the pharma industry and drug pricing. HHS Secretary Azar, though, seems to be serious about making changes.

Weekly Roundup

Markets consolidate after recent gains

Amgen, Novartis Clinch FDA Nod on Migraine Prevention Drug

Amgen, Novartis Clinch FDA Nod on Migraine Prevention Drug

Aimovig is the first treatment approved by the agency to prevent migraines by blocking the calcitonin gene-related peptide receptor.

Jim's Daily Rundown

Jim discusses Macy's quarter as a readthrough to Nordstrom, defense and North Korea, and more on the market!

With Everything Going On in the World, Corporate America Is Way Too Bullish

With Everything Going On in the World, Corporate America Is Way Too Bullish

Corporate America may not be giving it straight to investors. That could come back to bite them in the remaining quarters of 2018.

Berkshire Hathaway, Align Technology, Seaspan: 'Mad Money' Lightning Round

Berkshire Hathaway, Align Technology, Seaspan: 'Mad Money' Lightning Round

Jim Cramer focuses on Berkshire Hathaway, Align Technology, Seaspan, Criticare Systems, CoreSite Realty, Hi-Crush Partners and more.

Is This Rally for Real?: Cramer's 'Mad Money' Recap (Monday 5/14/18)

Is This Rally for Real?: Cramer's 'Mad Money' Recap (Monday 5/14/18)

Jim Cramer asks, why is there such a double-standard? Why do selloffs have instant credibility and advances are to be doubted?

Trimming Lilly; Adding WestRock and Textron

Taking advantage of recent gains in Lilly to shift more allocation to WestRock and Textron.

Being Bullish on Trump Surprisingly Worked Well for Investors This Week

Being Bullish on Trump Surprisingly Worked Well for Investors This Week

President Trump reduced tensions in Korea, raised them in the Middle East, and mainly relieved them for investors in the drug and healthcare industries.

Weekly Roundup

The markets strongly rebounded this week as a few of the major averages pushed into positive year-to-date territory.

Verizon, Chipotle, Bank of Internet: 'Mad Money' Lightning Round

Verizon, Chipotle, Bank of Internet: 'Mad Money' Lightning Round

Jim Cramer takes a look at Verizon, Chipotle, Bank of Internet, Oracle, PayPal, Raytheon, Mallinckrodt, Roku, McDonald's.

Markets Taking a Friday Breather

After a strong week, the stock market is being more temperate.

Stealth Rally: Cramer's 'Mad Money' Recap (Thursday 5/10/18)

Stealth Rally: Cramer's 'Mad Money' Recap (Thursday 5/10/18)

Take one part great earnings and one part tremendous skepticism, add in low inflation and you end up with this astonishing stealth rally. Jim Cramer explains it.

Closing Bell: LIVE MARKETS BLOG

Closing Bell: LIVE MARKETS BLOG

All three major averages closed Thursday's session in positive territory.

Lilly Acquiring ARMO BioSciences

Move boosts Lilly's presence in late-stage immuno-oncology.

Jim's Daily Rundown

Jim discusses expectations for Nvidia's earnings release, oil and our initiation in Anadarko Petroleum.

Elanco Animal Health Announces Addition Of General Counsel

Indiana-based company adds Michael-Bryant Hicks to leadership team

Last Week's Portfolio Changes

We initiated 2 new positions and exited another during a busy week for the portfolio.

Weekly Roundup

A strong Friday failed to keep markets in positive territory.

Teva Shows Progress on Restructuring But Investors Want More

Teva Shows Progress on Restructuring But Investors Want More

The Israel-based drugmaker reported first-quarter numbers that surpassed analysts' expectations but Wall Street wants to see more.

Buying More JPMorgan Chase

This is an opportunity to add to our position in this best-in-class financial at our lowest price to date.

Selling Some Lilly; Adding to PepsiCo

We will make a small sale in LLY and use the proceeds and opportunity to scoop up more PEP.

TheStreet Quant Rating: C+ (Hold)